The strategy of CCK2R targeting with radiolabeled gastrin analogs for diagnostic and therapeutic application in patients with advanced tumors, in particular MTC, has been pursued for more than two decades. This evidence concerns the gene GAST and medullary thyroid gland carcinoma.